Health Blueprint

Back to Longevity News

News summary

Amsterdam’s VectorY Therapeutics raises €74.5 million to tackle ALS and other neurodegenerative diseases

Source: EU-Startups Funding • Published: 13 Nov 2026, 07:11

Summarized by Masters of Longevity from EU-Startups Funding.

Amsterdam biotech raised €74.5 million to fund ALS and neurodegeneration programs.

Amsterdam’s VectorY Therapeutics raises €74.5 million to tackle ALS and other neurodegenerative diseases
Key Takeaways
  • VectorY raised €74.5M to fund its therapeutic programs.
  • New investors included Angelini Ventures, Invest-NL, and EIB.
  • This financing has not established human clinical efficacy.
Read the full article at EU-Startups Funding ↗

Continue exploring

Recommended MoL Picks

MoL PickLongevity is leaving the clinicStephen Watson argues that hotels, gyms and residential communities can build longevity memberships around the relationships they already have.MoL PickMOTS-c: Where the Evidence EndsStudies offer clues about ageing and metabolism. What do they actually tell us about human health—and where does expert opinion take over?MoL PickWhat Changes in the Human Hippocampus with Age?A study of 40 postmortem brains maps a midlife shift in immune cells and a wider loss of cellular and genome organisation—but it does not show how to prevent cognitive decline.